# Study on Autophagy Death of Alpha TC1 Clone 6 (αTC1-6) Cells Induced by Trametenolic Acid Through PI3K/AKT Pathway

**Authors:** Wangyang Ye, Shangling Pan, Hongqi Zhang, Xiaolan Zhang, Junzhi Wang

PMC · DOI: 10.3390/cimb47100871 · Current Issues in Molecular Biology · 2025-10-21

## TL;DR

This study shows that Trametenolic Acid inhibits glucagon secretion and cell proliferation in pancreatic alpha cells by inducing autophagy through the PI3K/AKT pathway.

## Contribution

The study identifies Trametenolic Acid as a potential therapeutic agent for glucagonoma by inducing autophagy via the PI3K/AKT pathway.

## Key findings

- TA significantly inhibits αTC1-6 cell proliferation in a dose- and time-dependent manner.
- TA reduces glucagon secretion and induces autophagy in αTC1-6 cells.
- TA inhibits phosphorylation of PI3K, AKT, mTOR, and increases FoxO1 expression.

## Abstract

Glucagonoma, a rare neuroendocrine tumor, lacks targeted treatment drugs. Excessive secretion of glucagon is the main cause of its clinical syndrome. To explore targeted therapeutic drugs that can inhibit glucagon secretion and tumor proliferation, we investigated the effect of Trametenolic Acid (TA) on mouse pancreatic alpha TC1 clone 6 (αTC1-6) cells and its regulatory role in the PI3K/AKT signaling pathway. Cell viability of αTC1-6 cells was assessed via the MTT assay. Glucagon content in cell culture supernatants was measured using an Enzyme-Linked Immunosorbent Assay (ELISA). Autophagic vacuoles were visualized through Monodansylcadaverine (MDC) staining. The expression of autophagy-related proteins including Atg7, LC3 Ⅱ and PI3K/AKT signaling pathway-related proteins mTOR and FoxO1 were determined by Western blot. The results showed that the proliferation of αTC1-6 cells was significantly inhibited by TA in a dose- and time-dependent manner, and the IC50 was 140.71, 26.77 and 1.99 μM after treatment of 12, 24, and 48 h, respectively. The secretion of glucagon was significantly inhibited by TA. The MDC staining results showed that the fluorescent labeled autophagic vesicles in the TA group were increased. The Western blot results showed that the expression of Atg7 and LC3 Ⅱ was promoted by TA in a dose-dependent manner, the phosphorylation of PI3K, AKT, mTOR and FoxO1 was significantly inhibited, and the expression of FoxO1 protein was increased. These results demonstrated that TA can inhibit glucagon secretion, induce autophagy, and suppress cell proliferation in αTC1-6 cells. The mechanism may be associated with the PI3K/AKT signaling pathway.

## Linked entities

- **Proteins:** PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), AKT1 (AKT serine/threonine kinase 1), MTOR (mechanistic target of rapamycin kinase), FOXO1 (forkhead box O1), ATG7 (autophagy related 7), MAP1LC3A (microtubule associated protein 1 light chain 3 alpha)
- **Chemicals:** Trametenolic Acid (PubChem CID 12309443)
- **Diseases:** glucagonoma (MONDO:0019959)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Atg7 (autophagy related 7) [NCBI Gene 74244] {aka 1810013K23Rik, Agp7, Apg7l, Atg7l, Gm21553}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Gcg (glucagon) [NCBI Gene 14526] {aka GLP-1, Glu, PPG}, Foxo1 (forkhead box O1) [NCBI Gene 56458] {aka Afxh, FKHR, Fkhr1, Foxo1a}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}
- **Diseases:** Glucagonoma (MESH:D005935), tumor (MESH:D009369), neuroendocrine tumor (MESH:D018358)
- **Chemicals:** MDC (MESH:C008542), TA (-), MTT (MESH:C070243)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** alphaTC1-6 — Mus musculus (Mouse), Mouse islet cell adenoma, Cancer cell line (CVCL_B036)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12564410/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12564410/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12564410/full.md

---
Source: https://tomesphere.com/paper/PMC12564410